Temperature-sensitive liposomes for doxorubicin delivery under MRI guidance

Journal of Controlled Release

Volumn 143, Issue 1, 2010, Pages 120-127

  de Smet, Mariska ^a   Langereis, Sander ^b   den Bosch, Sandra van ^b   Grüll, Holger ^a,b  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b PHILIPS RESEARCH LABORATORIES   (Netherlands)

Author keywords

Drug delivery; Focused ultrasound; Hyperthermia; Image guidance; Liposome; Magnetic resonance imaging

Indexed keywords

CO-ENCAPSULATION; DOXORUBICIN; FOCUSED ULTRASOUND; HYPERTHERMIA; IMAGE GUIDANCE; IMAGE GUIDANCES; LOCAL DRUG DELIVERY; LOW TEMPERATURES; MAGNETIC RESONANCE IMAGES; MELTING PHASE TRANSITION; MRI CONTRAST AGENTS; RAPID RELEASE; TEMPERATURE-INDUCED; TEMPERATURE-SENSITIVE; THERAPEUTIC EFFICACY; TWO-TEMPERATURE;

DRUG DELIVERY; GADOLINIUM; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; PHASE TRANSITIONS; PHOSPHOLIPIDS; ULTRASONICS;

LIPOSOMES;

1 PALMITOYLGLYCEROPHOSPHOCHOLINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; GADOTERIDOL; MACROGOL 2000; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; CONTRAST ENHANCEMENT; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; ENCAPSULATION; HUMAN; HUMAN CELL; LIPID BILAYER; LIPOSOMAL DELIVERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE TRANSITION; PRIORITY JOURNAL; TEMPERATURE SENSITIVITY;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CONTRAST MEDIA; DOXORUBICIN; DRUG COMPOUNDING; HETEROCYCLIC COMPOUNDS; HUMANS; KINETICS; LIPIDS; LIPOSOMES; MAGNETIC RESONANCE IMAGING; ORGANOMETALLIC COMPOUNDS; POLYETHYLENE GLYCOLS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TRANSITION TEMPERATURE;

EID: 77950518813     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.12.002     Document Type: Article

References (45)

1. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
2. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007, 9:E128-E147.
3. Gabizon A. Pharmacokinetics of PEGylated liposomal doxorubicin. Clin. Pharmacokinet. 2003, 42:419-436.
4. Abraham S.A., Waterhouse D.N., Lawrence D., Mayer D., Cullis P.R., Madden T.D., Bally M.B. The liposomal formulation of doxorubicin. Methods Enzymol. 2005, 391:71-97.
5. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in poly-ethylene-glycol coated liposomes. Cancer Res. 1994, 54:987-992.
6. Gaber M.H., Wu N.Z., Hong K., Huang S.K., Dewhirst M.W., Papahadjopoulos D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int. J. Radiat. Oncol. Biol. Phys. 1996, 36:1177-1187.
7. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
8. Gabizon A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992, 52:891-896.
9. Lu W.-L., Qi X.-R., Zhang Q., Li R.-Y., Wang G.-L., Zhang R.-J., Wei S.-L. A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. J. Pharmacol. Sci. 2004, 95:381-389.
10. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51:691-743.
11. Drummond D.C., Noble C.O., Hayes M.E., Park J.W., Kirpotin D.B. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J. Pharm. Sci. 2008, 97:4696-4740.
12. Northfelt D.W., Martin F.J., Working P., Volberding P.A., Russell J., Newman M., Amantea M.A., Kaplan L.D. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's Sarcoma. J. Clin. Pharmacol. 1996, 36:55-63.
13. Northfelt D.W., Dezube B.J., Thommes J.A., Miller B.J., Fischl M.A., Friedman-Kien A., Kaplan L.D., Du Mond C., Mamelok R.D., Henry D.H. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's Sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol. 1998, 16:2445-2451.
14. Judson I., Radford J.A., Harris M., Blay J.-Y., van Hoesel Q., le Cesne A., van Oosterom A.T., Clemons M.J., Kamby C., Hermans C., Whittaker J., Donato di Paola E., Verweij J., Nielsen S. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX ®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 2001, 37:870-877.
15. Harris L., Batist G., Belt R., Rovira D., Navari R., Azarnia N., Welles L., Winer E. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002, 94:25-36.
16. O'Brien M.E.R., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., Catane R., Kieback D.G., Tomczak P., Ackland S.P., Orlandi F., Mellars L., Alland L., Tendler C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15:440-449.
17. Yatvin M.B., Weinstein J.N., Dennis W.H., Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978, 202:1290-1293.
18. Gaber M.H., Hong K., Huang S.K., Papahadjopoulos D. Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma. Pharm. Res. 1995, 12:1407-1416.
19. Lindner L.H., Eichhorn M.E., Eibl H., Teichert N., Schmitt-Sody M., Issels R.D., Dellian M. Novel temperature-sensitive liposomes with prolonged circulation time. Clin. Cancer Res. 2004, 10:2168-2178.
20. Anyarambhatla G.R., Needham D. Enhancement of the phase transition permeability of DPPC liposomes by incorporation of MPPC: a new temperature-sensitive liposome for use with mild hyperthermia. J. Liposome Res. 1999, 9:491-506.
21. Kong G., Anyarambhatla G., Petros W.P., Braun R.D., Colvin O.M., Needham D., Dewhirst M.W. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000, 60:6950-6957.
22. Needham D., Anyarambhatla G., Kong G., Dewhirst M.W. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000, 60:1197-1201.
23. Mills J.K., Needham D. The materials engineering of temperature-sensitive liposomes. Methods Enzymol. 2004, 387:82-113.
24. Fossheim S.L., Il'yasov K.A., Hennig J., Bjørnerud A. Thermosensitive paramagnetic liposomes for temperature control during MR imaging-guided hyperthermia: in vitro feasibility studies. Acad. Radiol. 2000, 7.
25. Frich L., Bjørnerud A., Fossheim S., Tillung T., Gladhaug I. Experimental application of thermosensitive paramagnetic liposomes for monitoring magnetic resonance imaging guided thermal ablation. Magn. Reson. Med. 2004, 52:1302-1309.
26. McDannold N., Fossheim S.L., Rasmussen H., Martin H., Vykhodtseva N., Hynynen K. Heat-activated liposomal MR contrast agent: initial in vivo results in rabbit liver and kidney. Radiology 2004, 230:743-752.
27. Bos C., Lepetit-Coiffe M., Quesson B., Moonen C.T.W. Simultaneous monitoring of temperature and T1: methods and preliminary results of application to drug delivery using thermosensitive liposomes. Magn. Reson. Med. 2005, 54:1020-1024.
28. Salomir R., Palussiere J., Fossheim S.L., Rogstad A., Wiggen U.N., Grenier N., Moonen C.T.W. Local delivery of magnetic resonance (MR) contrast agent in kidney using thermosensitive liposomes and MR imaging-guided local hyperthermia: a feasibility study in vivo. J. Magn. Reson. Imaging 2005, 22:534-540.
29. Peller M., Schwerdt A., Hossan M., Reinl H.M., Wang T., Sourbron S., Ogris M., Lindner L.H. MR characterization of mild hyperthermia-induced gadodiamide release from thermosensitive liposomes in solid tumors. Invest. Radiol. 2008, 43:877-892.
30. 19F contrast agent for MR image-guided drug delivery. J. Am. Chem. Soc. 2009, 131:1380-1381.
31. 1-shortening gadodiamide. Contrast Media Mol. Imaging 2008, 3:19-26.
32. Abraham S.A., Edwards K., Karlsson G., MacIntosh S., Mayer L.D., McKenzie C., Bally M.B. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim. Biophys. Acta 2002, 1565:41-54.
33. Chiu G.N.C., Abraham S.A., Ickenstein L.M., Ng R., Karlsson G., Edwards K., Wasan E.K., Bally M.B. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J. Control. Release 2005, 104:271-288.
34. Viglianti B.L., Abraham S.A., Michelich C.R., Yarmolenko P.S., MacFall J.R., Bally M.B., Dewhirst M.W. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn. Reson. Med. 2004, 51:1153-1162.
35. Viglianti B.L., Ponce A.M., Michelich C.R., Yu D., Abraham S.A., Sanders L., Yarmolenko P.S., Schroeder T., MacFall J.R., Barboriak D.P., Colvin O.M., Bally M.B., Dewhirst M.W. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn. Reson. Med. 2006, 56:1011-1018.
36. Ponce A.M., Viglianti B.L., Yu D., Yarmolenko P.S., Michelich C.R., Woo J., Bally M.B., Dewhirst M.W. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J. Natl. Cancer Inst. 2007, 99:53-63.
37. Koretsky A.P., Silva A.C. Manganese-enhanced magnetic resonance imaging (MEMRI). NMR Biomed. 2004, 17:527-531.
38. Silva A.C., Lee J.H., Aoki I., Koretsky A.P. Manganese-enhanced magnetic resonance imaging (MEMRI): methodological and practical considerations. NMR Biomed. 2004, 17:532-543.
39. Koenig S.H., Ahkong G.F., Brown R.D., Lafleur M., Spiller M., Unger E., Tilcock C. Permeability of liposomal membranes to water: results from the magnetic field dependence of T1 of solvent protons in suspensions of vesicles with entrapped paramagnetic ions. Magn. Reson. Med. 1992, 23:275-286.
40. Terreno E., Sanino A., Carrera C., Delli Castelli D., Giovenzana G.B., Lombardi A., Mazzon R., Milone L., Visigalli M., Aime S. Determination of water permeability of paramagnetic liposomes of interest in MRI field. J. Inorg. Biochem. 2008, 102:1112-1119.
41. Haran G., Cohen R., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1993, 1151:201-215.
42. Li X., Hirsh D.J., Cabral-Lilly D., Zirkel A., Gruner S.M., Janoff A.S., Perkins W.R. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim. Biophys. Acta 1998, 1415:23-40.
43. Unger E., Shen D.K., Wu G.L., Fritz T. Liposomes as MR contrast agents: pros and cons. Magn. Reson. Med. 1991, 22:304-308.
44. Mulkern R.V., Bleier A.R., Adzamli I.K., Spencer R.G., Sandor T., Jolesz F.A. Two-site exchange revisited: a new method for extracting exchange parameters in biological systems. Biophys. J. 1989, 55:221-232.
45. Sandström M.C., Ickenstein L.M., Mayer L.D., Edwards K. Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes. J. Control. Release 2005, 107:131-142.